In a groundbreaking Phase III trial, drugmaker AstraZeneca’s Farxiga has shown reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease.
As reported by Health Europa, detailed results from the Phase III DAPA-CKD trial have shown that AstraZeneca’s Farxiga (dapagliflozin) reduced the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39 percent, compared to placebo in patients with chronic kidney disease at stages 2-4 and elevated urinary albumin excretion.
The results were consistent in patients both with and without Type 2 diabetes.
Chronic kidney disease is a serious, progressive condition defined by decreased kidney function affecting nearly 700 million people worldwide, many of them still undiagnosed, and the most common causes are diabetes, hypertension, and glomerulonephritis.
DAPA-CKD is an international, multi-centre, randomised, double-blinded trial in 4,304 patients designed to evaluate the efficacy of Farxiga 10mg, compared with placebo, in patients with CKD Stages 2-4 and elevated urinary albumin excretion, with and without Type 2 diabetes.
The primary composite endpoint was 50 percent sustained decline in estimated glomerular filtration rate, onset of end-stage kidney disease (and cardiovascular or renal death.
The absolute risk reduction was 5.3 percent over the median time in study of 2.4 years. The trial also met all secondary endpoints, including significantly reducing death from any cause by 31 percent, compared to placebo.
The co-chairs of the DAPA-CKD trial and its Executive Committee Professor David Wheeler, University College London, UK and Professor Hiddo L. Heerspink, University Medical Center Groningen, the Netherlands, said: “The impressive DAPA-CKD trial results are a remarkable development for patients with chronic kidney disease.
“These data have the potential to transform the standard of care for this patient population, which has a significant unmet need for new and improved treatment options.”
The post Drug offers improved survival in patients with chronic kidney disease appeared first on Healthwise.